{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:49:49Z","timestamp":1793328589287,"version":"4.5.0"},"reference-count":164,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NIAID","award":["R01AI175439"],"award-info":[{"award-number":["R01AI175439"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Flaviviruses are arthropod-borne RNA viruses that can cause a wide range of human diseases, from mild symptoms to severe illness with multiorgan failure and death. Effective prevention of these diseases relies on identifying reliable vaccine targets, typically measured by correlates of protection (CoPs), which help indicate host immunity after vaccination. Current vaccines primarily focus on neutralizing antibodies (nAbs) against the viral envelope E protein, though emerging evidence suggests other potential targets may also be effective in disease prevention. Additionally, there is growing evidence of cross-protection between different flaviviruses when immunity to one virus is achieved, although this can be limited by antibody-dependent enhancement. This review examines the current understanding of flavivirus immunity, CoPs, and the potential for cross-protection in the context of existing vaccine strategies.<\/jats:p>","DOI":"10.3390\/vaccines13050449","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T06:18:02Z","timestamp":1745475482000},"page":"449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity"],"prefix":"10.3390","volume":"13","author":[{"given":"Hannah E.","family":"Flores","sequence":"first","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-143X","authenticated-orcid":false,"given":"Eduar Fernando","family":"Pinzon Burgos","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Camacho Ortega","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-8504","authenticated-orcid":false,"given":"Alonso","family":"Heredia","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-4672","authenticated-orcid":false,"given":"Joel V.","family":"Chua","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"ref_1","unstructured":"Bennett, J.E., Dolin, R., and Blaser, M.J. (2020). Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases, Elsevier. [9th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1016\/j.vaccine.2011.09.114","article-title":"Flaviviruses and flavivirus vaccines","volume":"30","author":"Heinz","year":"2012","journal-title":"Vaccine"},{"key":"ref_3","unstructured":"Martin, C.R., Martin, C.J.H., Preedy, V.R., and Rajendram, R. (2021). Chapter 1\u2014Flaviviruses and where the Zika virus fits in: An overview. Zika Virus Biology, Transmission, and Pathology, Academic Press."},{"key":"ref_4","unstructured":"Simon, L.V., Hashmi, M.F., and Torp, K.D. (2024). Yellow Fever. StatPearls, StatPearls Publishing. Treasure Island (FL) ineligible companies. Disclosure: Muhammad Hashmi declares no relevant financial relationships with ineligible companies. Disclosure: Klaus Torp declares no relevant financial relationships with ineligible companies."},{"key":"ref_5","unstructured":"Schaefer, T.J., Panda, P.K., and Wolford, R.W. (2024). Dengue Fever. StatPearls, StatPearls Publishing. Treasure Island (FL) ineligible companies. Disclosure: Prasan Panda declares no relevant financial relationships with ineligible companies. Disclosure: Robert Wolford declares no relevant financial relationships with ineligible companies."},{"key":"ref_6","unstructured":"Simon, L.V., Sandhu, D.S., Goyal, A., and Kruse, B. (2024). Japanese Encephalitis. StatPearls, StatPearls Publishing. Treasure Island (FL) ineligible companies. Disclosure: Divyajot Sandhu declares no relevant financial relationships with ineligible companies. Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies. Disclosure: Brian Kruse declares no relevant financial relationships with ineligible companies."},{"key":"ref_7","unstructured":"Clark, M.B., and Schaefer, T.J. (2024). West Nile Virus. StatPearls, StatPearls Publishing. Treasure Island (FL) ineligible companies. Disclosure: Timothy Schaefer declares no relevant financial relationships with ineligible companies."},{"key":"ref_8","unstructured":"Wolford, R.W., and Schaefer, T.J. (2024). Zika Virus. StatPearls, StatPearls Publishing. Treasure Island (FL) ineligible companies. Disclosure: Timothy Schaefer declares no relevant financial relationships with ineligible companies."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"ref_10","unstructured":"World Health Organization (2023). Yellow Fever."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhao, R., Wang, M., Cao, J., Shen, J., Zhou, X., Wang, D., and Cao, J. (2021). Flavivirus: From Structure to Therapeutics Development. Life, 11.","DOI":"10.3390\/life11070615"},{"key":"ref_12","unstructured":"Vega, F.E., and Kaya, H.K. (2012). Chapter 5\u2014RNA Viruses Infecting Pest Insects. Insect Pathology, Academic Press. [2nd ed.]."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.mib.2008.06.004","article-title":"Structural proteomics of dengue virus","volume":"11","author":"Perera","year":"2008","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1080\/21505594.2021.1996059","article-title":"Pathogenesis and virulence of flavivirus infections","volume":"12","author":"Heunis","year":"2021","journal-title":"Virulence"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"199018","DOI":"10.1016\/j.virusres.2022.199018","article-title":"Dengue virus infection\u2014A review of pathogenesis, vaccines, diagnosis and therapy","volume":"324","author":"Kok","year":"2023","journal-title":"Virus Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1128\/JVI.00291-08","article-title":"Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo","volume":"82","author":"Goncalvez","year":"2008","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.chom.2016.04.013","article-title":"Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody","volume":"19","author":"Dai","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1038\/emboj.2009.245","article-title":"Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody","volume":"28","author":"Cherrier","year":"2009","journal-title":"Embo J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/emboj.2011.439","article-title":"Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus","volume":"31","author":"Cockburn","year":"2012","journal-title":"Embo J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1128\/JVI.02411-14","article-title":"Structure of acidic pH dengue virus showing the fusogenic glycoprotein trimers","volume":"89","author":"Zhang","year":"2015","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1016\/j.celrep.2019.02.062","article-title":"Structural Basis for Neutralization and Protection by a Zika Virus-Specific Human Antibody","volume":"26","author":"Wang","year":"2019","journal-title":"Cell Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12400","DOI":"10.1073\/pnas.0603488103","article-title":"West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody","volume":"103","author":"Kaufmann","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nsmb.1382","article-title":"Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins","volume":"15","author":"Lok","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.4049\/jimmunol.1200227","article-title":"Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity","volume":"188","author":"Midgley","year":"2012","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Austin, S.K., Dowd, K.A., Shrestha, B., Nelson, C.A., Edeling, M.A., Johnson, S., Pierson, T.C., Diamond, M.S., and Fremont, D.H. (2012). Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002930"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.str.2012.01.001","article-title":"Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody","volume":"20","author":"Cockburn","year":"2012","journal-title":"Structure"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature14130","article-title":"Recognition determinants of broadly neutralizing human antibodies against dengue viruses","volume":"520","author":"Rouvinski","year":"2015","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nature18938","article-title":"Structural basis of potent Zika\u2013dengue virus antibody cross-neutralization","volume":"536","author":"Dejnirattisai","year":"2016","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kaufmann, B., Chipman, P.R., Holdaway, H.A., Johnson, S., Fremont, D.H., Kuhn, R.J., Diamond, M.S., and Rossmann, M.G. (2009). Capturing a flavivirus pre-fusion intermediate. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000672"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Plotkin, S.A. (2022). Recent updates on correlates of vaccine-induced protection. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1081107"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Haks, M.C., Bottazzi, B., Cecchinato, V., De Gregorio, C., Del Giudice, G., Kaufmann, S.H.E., Lanzavecchia, A., Lewis, D.J.M., Maertzdorf, J., and Mantovani, A. (2017). Molecular Signatures of Immunity and Immunogenicity in Infection and Vaccination. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01563"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14760584.2024.2331065","article-title":"The durability of vaccine-induced protection: An overview","volume":"23","author":"Vashishtha","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dutta, S.K., and Langenburg, T. (2023). A Perspective on Current Flavivirus Vaccine Development: A Brief Review. Viruses, 15.","DOI":"10.3390\/v15040860"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.vaccine.2014.01.040","article-title":"A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available","volume":"32","author":"Ishikawa","year":"2014","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s43856-023-00378-7","article-title":"Neutralizing antibodies from prior exposure to dengue virus negatively correlate with viremia on re-infection","volume":"3","author":"Anantharaj","year":"2023","journal-title":"Commun. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2021055522","DOI":"10.1542\/peds.2021-055522","article-title":"Dengue: A Growing Problem with New Interventions","volume":"149","author":"Wong","year":"2022","journal-title":"Pediatrics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.virol.2022.06.011","article-title":"Genetic diversity and spatiotemporal dynamics of DENV-1 and DENV-2 infections during the 2012\u20132013 outbreak in Mexico","volume":"573","year":"2022","journal-title":"Virology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/22221751.2021.1899057","article-title":"Viral evolution sustains a dengue outbreak of enhanced severity","volume":"10","author":"Inizan","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41467-023-44330-8","article-title":"Protection against symptomatic dengue infection by neutralizing antibodies varies by infection history and infecting serotype","volume":"15","author":"Bos","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4269\/ajtmh.1983.32.154","article-title":"Original antigenic sin in dengue","volume":"32","author":"Halstead","year":"1983","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.1522136113","article-title":"Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort","volume":"113","author":"Katzelnick","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41586-018-0157-4","article-title":"Reconstruction of antibody dynamics and infection histories to evaluate dengue risk","volume":"557","author":"Salje","year":"2018","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/microbiolspec.AID-0022-2014","article-title":"Dengue Antibody-Dependent Enhancement: Knowns and Unknowns","volume":"2","author":"Halstead","year":"2014","journal-title":"Microbiol. Spectr"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00284-020-02284-w","article-title":"Current Understanding of the Pathogenesis of Dengue Virus Infection","volume":"78","author":"Bhatt","year":"2021","journal-title":"Curr. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1073\/pnas.0832193100","article-title":"A ligand-binding pocket in the dengue virus envelope glycoprotein","volume":"100","author":"Modis","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","article-title":"Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells","volume":"75","author":"Crill","year":"2001","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Sarker, A., Dhama, N., and Gupta, R.D. (2023). Dengue virus neutralizing antibody: A review of targets, cross-reactivity, and antibody-dependent enhancement. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1200195"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e019368","DOI":"10.1136\/bmjopen-2017-019368","article-title":"Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: Systematic review and meta-analysis","volume":"9","author":"Rosa","year":"2019","journal-title":"BMJ Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Hou, J., Ye, W., and Chen, J. (2022). Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.840104"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/QCO.0000000000000871","article-title":"Dengue vaccine development: Challenges and prospects","volume":"35","year":"2022","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41541-024-00967-0","article-title":"Long term T cell response and safety of a tetravalent dengue vaccine in healthy children","volume":"9","author":"Mandaric","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"100604","DOI":"10.1016\/j.jvacx.2024.100604","article-title":"Current status of the development of dengue vaccines","volume":"22","author":"Lee","year":"2025","journal-title":"Vaccine X"},{"key":"ref_62","first-page":"199","article-title":"Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group","volume":"80","author":"Fernando","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: A two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1473-3099(24)00376-1","article-title":"Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: Results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil","volume":"24","author":"Nogueira","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_65","first-page":"1","article-title":"Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Hills","year":"2019","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4161\/21645515.2014.983412","article-title":"Product review on the JE vaccine IXIARO","volume":"11","author":"Firbas","year":"2015","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1084\/jem.20031223","article-title":"A critical role for induced IgM in the protection against West Nile virus infection","volume":"198","author":"Diamond","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1086\/376870","article-title":"Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice","volume":"188","author":"Lustig","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.65.6.787","article-title":"The use of yellow fever virus modified by in vitro cultivation for human immunization","volume":"65","author":"Theiler","year":"1937","journal-title":"J. Exp. Med."},{"key":"ref_70","first-page":"895","article-title":"Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull. World Health Organ."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4269\/ajtmh.2011.10-0496","article-title":"Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil","volume":"85","author":"Bertani","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/14760584.2016.1198259","article-title":"Questions regarding the safety and duration of immunity following live yellow fever vaccination","volume":"15","author":"Amanna","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","article-title":"Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: Phase 1, randomised, double-blind, placebo-controlled clinical trials","volume":"391","author":"Modjarrad","year":"2018","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S1473-3099(23)00192-5","article-title":"Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: A phase 1, randomised, double-blind, placebo-controlled clinical trial","volume":"23","author":"Koren","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4269\/ajtmh.2009.08-0625","article-title":"Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance","volume":"81","author":"Thomas","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1099\/vir.0.000075","article-title":"Spectrum of disease outcomes in mice infected with YFV-17D","volume":"96","author":"Erickson","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_79","first-page":"269","article-title":"Vaccines and vaccination against yellow fever: WHO position paper\u2014June 2013","volume":"88","year":"2013","journal-title":"Wkly. Epidemiol. Rec."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3201\/eid2305.161630","article-title":"Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection","volume":"23","author":"Collins","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e2250133","DOI":"10.1002\/eji.202250133","article-title":"YF17D-based vaccines\u2014Standing on the shoulders of a giant","volume":"54","author":"Alpizar","year":"2024","journal-title":"Eur J. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0166-0934(03)00128-9","article-title":"MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination","volume":"110","author":"Pupo","year":"2003","journal-title":"J. Virol. Methods"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/am.25.4.539-544.1973","article-title":"Yellow fever vaccine: Direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.16-0401","article-title":"A Meta-Analysis of Serological Response Associated with Yellow Fever Vaccination","volume":"95","author":"Jean","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1097\/QAD.0000000000001963","article-title":"Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients","volume":"32","author":"Durier","year":"2018","journal-title":"Aids"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-023-00629-7","article-title":"Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models","volume":"8","author":"Jasny","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Garg, H., Mehmetoglu-Gurbuz, T., and Joshi, A. (2020). Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-61103-1"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00705-022-05481-z","article-title":"Molecular pathogenesis of Japanese encephalitis and possible therapeutic strategies","volume":"167","author":"Kumar","year":"2022","journal-title":"Arch. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41541-021-00338-z","article-title":"The future of Japanese encephalitis vaccination: Expert recommendations for achieving and maintaining optimal JE control","volume":"6","author":"Vannice","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_91","unstructured":"(2024). Japanese Encephalitis, World Health Organization."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2343910","DOI":"10.1080\/22221751.2024.2343910","article-title":"Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus","volume":"13","author":"Kim","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Letson, G.W., Marfin, A.A., Mooney, J., Minh, H.V., and Hills, S.L. (2024). Impact of vaccination against Japanese encephalitis in endemic countries. PLoS Negl. Trop. Dis., 18.","DOI":"10.1371\/journal.pntd.0012390"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Kalimuddin, S., Chan, Y.F.Z., Sessions, O.M., Chan, K.R., Ong, E.Z., Low, J.G., Bertoletti, A., and Ooi, E.E. (2023). An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1135979"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"199376","DOI":"10.1016\/j.virusres.2024.199376","article-title":"Japanese encephalitis virus E protein domain III immunization mediates cross-protection against Zika virus in mice via antibodies and CD8+ T cells","volume":"345","author":"Duan","year":"2024","journal-title":"Virus Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0042-6822(91)90034-9","article-title":"Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection","volume":"180","author":"Mason","year":"1991","journal-title":"Virology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e28700","DOI":"10.1002\/jmv.28700","article-title":"Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials","volume":"95","author":"Dia","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1016\/j.vaccine.2011.06.062","article-title":"Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO\u00ae) induced neutralizing antibody titers","volume":"29","author":"Klade","year":"2011","journal-title":"Vaccine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.4161\/21645515.2014.980197","article-title":"Immunogenicity and safety of currently available Japanese encephalitis vaccines: A systematic review","volume":"10","author":"Li","year":"2014","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0264-410X(00)00038-4","article-title":"Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines","volume":"18","author":"Markoff","year":"2000","journal-title":"Vaccine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"104930","DOI":"10.1016\/j.antiviral.2020.104930","article-title":"Identification of a protective epitope in Japanese encephalitis virus NS1 protein","volume":"182","author":"Zhou","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrmicro2950","article-title":"West Nile virus infection and immunity","volume":"11","author":"Suthar","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"11416","DOI":"10.1128\/JVI.01488-13","article-title":"The Essential, Nonredundant Roles of RIG-I and MDA5 in Detecting and Controlling West Nile Virus Infection","volume":"87","author":"McMillan","year":"2013","journal-title":"J. Virol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41564-019-0375-z","article-title":"Identification of antiviral roles for the exon\u2013junction complex and nonsense-mediated decay in flaviviral infection","volume":"4","author":"Li","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.virol.2005.07.013","article-title":"Gene expression in mice infected with West Nile virus strains of different neurovirulence","volume":"342","author":"Venter","year":"2005","journal-title":"Virology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.vetimm.2008.02.002","article-title":"A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse","volume":"123","author":"Minke","year":"2008","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_107","first-page":"221","article-title":"Equine vaccine for West Nile virus","volume":"114","author":"Ng","year":"2003","journal-title":"Dev. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Naveed, A., Eertink, L.G., Wang, D., and Li, F. (2024). Lessons Learned from West Nile Virus Infection:Vaccinations in Equines and Their Implications for One Health Approaches. Viruses, 16.","DOI":"10.3390\/v16050781"},{"key":"ref_109","unstructured":"(2025, April 22). A Study to Evaluate the Safety and Efficacy of a West Nile Virus Vaccine in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00746798."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJMp2301816","article-title":"Combating West Nile Virus Disease\u2014Time to Revisit Vaccination","volume":"388","author":"Gould","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14760584.2017.1357471","article-title":"Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases","volume":"16","author":"Barrett","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_112","unstructured":"Infectious Diseases Clinical Research Consortium (IDCRC). IDCRC Launches Clinical Trial to Study the Safety and Immunogenicity of an Inactivated West Nile Virus vaccine. Infectious Diseases Clinical Research Consortium. Accessed 22 April, 2025."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(59)91362-5","article-title":"A Simple Plaque Inhibition Test for Antiviral Agents: Application to Assay of Interferon","volume":"274","author":"Porterfield","year":"1959","journal-title":"Lancet"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1086\/427945","article-title":"Use of Interferon-\u03b1 in Patients with West Nile Encephalitis: Report of 2 Cases","volume":"40","author":"Kalil","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2125.1998.00836.x","article-title":"Ribavirin and interferon alfa-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions","volume":"46","author":"Khakoo","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3201\/eid0801.010252","article-title":"Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro","volume":"8","author":"Anderson","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nm1240","article-title":"Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus","volume":"11","author":"Oliphant","year":"2005","journal-title":"Nat. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1128\/JVI.77.4.2578-2586.2003","article-title":"B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus","volume":"77","author":"Diamond","year":"2003","journal-title":"J. Virol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"13323","DOI":"10.1128\/JVI.77.24.13323-13334.2003","article-title":"CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis","volume":"77","author":"Wang","year":"2003","journal-title":"J. Virol."},{"key":"ref_120","first-page":"3266","article-title":"Tregs control the development of symptomatic West Nile virus infection in humans and mice","volume":"119","author":"Lanteri","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Koblischke, M., Spitzer, F.S., Florian, D.M., Aberle, S.W., Malafa, S., Fae, I., Cassaniti, I., Jungbauer, C., Knapp, B., and Laferl, H. (2020). CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00016"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.4049\/jimmunol.181.12.8568","article-title":"West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection","volume":"181","author":"Brien","year":"2008","journal-title":"J. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Koblischke, M., Stiasny, K., Aberle, S.W., Malafa, S., Tsouchnikas, G., Schwaiger, J., Kundi, M., Heinz, F.X., and Aberle, J.H. (2018). Structural Influence on the Dominance of Virus-Specific CD4 T Cell Epitopes in Zika Virus Infection. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02083"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1128\/JVI.79.9.5665-5675.2005","article-title":"Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections","volume":"79","author":"Simmons","year":"2005","journal-title":"J. Virol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1084\/jem.20110740","article-title":"Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants","volume":"208","author":"Purtha","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Allman, W.R., Liu, L., Coleman, A.S., and Akkoyunlu, M. (2016). MRL Strains Have a BAFFR Mutation without Functional Consequence. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154518"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Giordano, D., Draves, K.E., Young, L.B., Roe, K., Bryan, M.A., Dresch, C., Richner, J.M., Diamond, M.S., Gale, M., and Clark, E.A. (2017). Protection of mice deficient in mature B cells from West Nile virus infection by passive and active immunization. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006743"},{"key":"ref_128","unstructured":"(2015). Zika: Symptoms, Prevention and Treatments, Pan American Health Organization."},{"key":"ref_129","unstructured":"(2025). Clinical Signs and Symptoms of Zika Virus Disease, Centers for Disease Control and Prevention."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Pattnaik, A., Sahoo, B.R., and Pattnaik, A.K. (2020). Current Status of Zika Virus Vaccines: Successes and Challenges. Vaccines, 8.","DOI":"10.3390\/vaccines8020266"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1128\/JVI.00354-15","article-title":"Biology of Zika Virus Infection in Human Skin Cells","volume":"89","author":"Hamel","year":"2015","journal-title":"J. Virol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.15252\/embr.201642627","article-title":"Zika virus inhibits type-I interferon production and downstream signaling","volume":"17","author":"Kumar","year":"2016","journal-title":"EMBO Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.chom.2016.03.010","article-title":"A Mouse Model of Zika Virus Pathogenesis","volume":"19","author":"Lazear","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20564","article-title":"Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice","volume":"540","author":"Sapparapu","year":"2016","journal-title":"Nature"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"369ra179","DOI":"10.1126\/scitranslmed.aai8336","article-title":"Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus","volume":"8","author":"Wang","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Pardy, R.D., Rajah, M.M., Condotta, S.A., Taylor, N.G., Sagan, S.M., and Richer, M.J. (2017). Analysis of the T Cell Response to Zika Virus and Identification of a Novel CD8+ T Cell Epitope in Immunocompetent Mice. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006184"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chom.2016.12.010","article-title":"Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice","volume":"21","author":"Vizcarra","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-018-05519-4","article-title":"Critical role of CD4+ T cells and IFN\u03b3 signaling in antibody-mediated resistance to Zika virus infection","volume":"9","author":"Lucas","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for Zika virus","volume":"354","author":"Dowd","year":"2016","journal-title":"Science"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine","volume":"385","author":"Tebas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: Randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: The results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1016\/j.mayocp.2019.05.016","article-title":"Zika Vaccine Development: Current Status","volume":"94","author":"Poland","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1126\/science.aaf5316","article-title":"The 3.8 \u00c5 resolution cryo-EM structure of Zika virus","volume":"352","author":"Sirohi","year":"2016","journal-title":"Science"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Deng, Y.Q., Dai, J.X., Ji, G.H., Jiang, T., Wang, H.J., Yang, H.O., Tan, W.L., Liu, R., Yu, M., and Ge, B.X. (2011). A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016059"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1128\/JVI.00316-08","article-title":"Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II","volume":"82","author":"Lai","year":"2008","journal-title":"J. Virol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1128\/JVI.00551-06","article-title":"Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus","volume":"80","author":"Throsby","year":"2006","journal-title":"J. Virol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"12149","DOI":"10.1128\/JVI.01732-06","article-title":"Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein","volume":"80","author":"Oliphant","year":"2006","journal-title":"J. Virol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Grifoni, A., Pham, J., Sidney, J., O\u2019Rourke, P.H., Paul, S., Peters, B., Martini, S.R., de Silva, A.D., Ricciardi, M.J., and Magnani, D.M. (2017). Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. J. Virol., 91.","DOI":"10.1128\/JVI.01469-17"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1073\/pnas.1607931113","article-title":"Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus","volume":"113","author":"Priyamvada","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1016\/j.vaccine.2023.04.015","article-title":"Impact of prior flavivirus vaccination on immunogenicity and efficacy of an inactivated Zika vaccine in Indian rhesus macaques","volume":"41","author":"Young","year":"2023","journal-title":"Vaccine"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molimm.2022.11.010","article-title":"Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis","volume":"152","author":"Thomas","year":"2022","journal-title":"Mol. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/315215","article-title":"Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity","volume":"181","author":"Vaughn","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0264-410X(02)00743-0","article-title":"Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex","volume":"21","author":"Lobigs","year":"2003","journal-title":"Vaccine"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.aaf8505","article-title":"Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection","volume":"353","author":"Stettler","year":"2016","journal-title":"Science"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus","volume":"17","author":"Dejnirattisai","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity","volume":"356","author":"Bardina","year":"2017","journal-title":"Science"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Chan, K.R., Wang, X., Saron, W.A.A., Gan, E.S., Tan, H.C., Mok, D.Z.L., Zhang, S.L., Lee, Y.H., Liang, C., and Wijaya, L. (2016). Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat. Microbiol., 1.","DOI":"10.1038\/nmicrobiol.2016.164"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1099\/vir.0.031641-0","article-title":"Flavivirus-induced antibody cross-reactivity","volume":"92","author":"Mansfield","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"He, J., Ding, X., Zhao, J., Zeng, J., Zhou, Y., Xiao, W., Hua, D., Liu, M., Guo, H., and Zhang, Y. (2024). A novel pan-epitope based nanovaccine self-assembled with CpG enhances immune responses against flavivirus. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-024-03031-0"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cell.2017.04.024","article-title":"Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico","volume":"169","author":"Robbiani","year":"2017","journal-title":"Cell"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e00745-20","DOI":"10.1128\/JVI.00745-20","article-title":"Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus","volume":"94","author":"Thomas","year":"2020","journal-title":"J. Virol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:20:39Z","timestamp":1760030439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":164,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["vaccines13050449"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13050449","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}